First Time Loading...

Netscientific PLC
LSE:NSCI

Watchlist Manager
Netscientific PLC Logo
Netscientific PLC
LSE:NSCI
Watchlist
Price: 67 GBX -2.9% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

NSCI doesn't have a meaningful market cap.

NetScientific Plc is a healthcare medical technology company, which engages in sourcing, funding, and commercializing technologies that improve the health and well-being of people with chronic disease... [ Read More ]

The intrinsic value of one NSCI stock under the Base Case scenario is 50.42 GBX. Compared to the current market price of 67 GBX, Netscientific PLC is Overvalued by 25%.

Key Points:
NSCI Intrinsic Value
Base Case
50.42 GBX
Overvaluation 25%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Netscientific PLC

Backtest NSCI Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling NSCI stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Netscientific PLC

Current Assets 1.6m
Cash & Short-Term Investments 852k
Receivables 550k
Other Current Assets 184k
Non-Current Assets 27.4m
Long-Term Investments 23.4m
PP&E 564k
Intangibles 3.4m
Current Liabilities 2.7m
Accounts Payable 497k
Accrued Liabilities 1.1m
Other Current Liabilities 1.2m
Non-Current Liabilities 389k
Long-Term Debt 987k
Other Non-Current Liabilities -598k
Efficiency

Earnings Waterfall
Netscientific PLC

Revenue
1.4m GBP
Cost of Revenue
-245k GBP
Gross Profit
1.1m GBP
Operating Expenses
-4.8m GBP
Operating Income
-3.6m GBP
Other Expenses
582k GBP
Net Income
-3.1m GBP

Free Cash Flow Analysis
Netscientific PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

NSCI Profitability Score
Profitability Due Diligence

Netscientific PLC's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
ROIC is Increasing
ROE is Increasing
33/100
Profitability
Score

Netscientific PLC's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

NSCI Solvency Score
Solvency Due Diligence

Netscientific PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Low D/E
Positive Net Debt
Short-Term Solvency
51/100
Solvency
Score

Netscientific PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NSCI Price Targets Summary
Netscientific PLC

Wall Street analysts forecast NSCI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NSCI is 191.76 GBX with a low forecast of 189.88 GBX and a high forecast of 197.4 GBX.

Lowest
Price Target
189.88 GBX
183% Upside
Average
Price Target
191.76 GBX
186% Upside
Highest
Price Target
197.4 GBX
195% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

NSCI Price
Netscientific PLC

1M 1M
+0%
6M 6M
+8%
1Y 1Y
-1%
3Y 3Y
+21%
5Y 5Y
-23%
10Y 10Y
-94%
Annual Price Range
67
52w Low
49
52w High
81
Price Metrics
Average Annual Return 9.85%
Standard Deviation of Annual Returns 69.57%
Max Drawdown -89%
Shares Statistics
Market Capitalization 15.7m GBX
Shares Outstanding 23 945 800
Percentage of Shares Shorted
N/A

NSCI Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Netscientific PLC Logo
Netscientific PLC

Country

United Kingdom

Industry

Health Care

Market Cap

15.7m GBP

Dividend Yield

0%

Description

NetScientific Plc is a healthcare medical technology company, which engages in sourcing, funding, and commercializing technologies that improve the health and well-being of people with chronic diseases. Its portfolio consists of a combination of direct investments and capital under advisory. The company has developed a customized investment and realization strategy for its portfolio companies through management, incubation, advisory services and fund-raising support. The company facilitates the companies it works with, to access the type of funding, management support and resources specific to their sector, stage of development and available opportunities. The firm's subsidiaries include EMV Capital Limited, Glycotest, Inc. and ProAxsis Limited, among others.

Contact

London
PO Box 76075
+442035141800.0
http://netscientific.net/

IPO

2013-09-16

Employees

13

Officers

CEO & Executive Director
Dr. Ilian Petkov Iliev Ph.D.
General Counsel, Group Company Secretary & Executive Director
Mr. Edward Benjamin Peter Hooper
Chief Financial Officer
Mr. Stephen Daniel Crowe
Investment Manager
Ms. Vyara Stoycheva
Marketing Manager
Ms. Anete Merhele
Human Resource Manager
Ms. Penny Turner
Show More
Head of Capital Raising & Co-Investment
Mr. Nick Salisbury
Venture Partner of Sustainability
Mr. Ian Cooke
Chief Executive Officer of PDS Biotechnology
Dr. Frank K. Bedu-Addo Ph.D.
Financial Controller
Ms. Hannah Jarvis
Show Less

See Also

Discover More
What is the Intrinsic Value of one NSCI stock?

The intrinsic value of one NSCI stock under the Base Case scenario is 50.42 GBX.

Is NSCI stock undervalued or overvalued?

Compared to the current market price of 67 GBX, Netscientific PLC is Overvalued by 25%.